

## This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
<b>Inflammation</b>				
Inflammatory diseases	L selectin (SELL; CD62L); P selectin (SELP; CD62P)	<i>In vitro</i> and mouse studies identified polyglycerol sulfate-based inhibitors of SELL and SELP that could help treat inflammatory diseases. In cell culture, the compounds inhibited SELL- and SELP-mediated leukocyte adhesion to human endothelial cells compared with no treatment. In a mouse model of contact dermatitis, one of the compounds decreased ear swelling about as much as prednisolone. In lipopolysaccharide (LPS)-challenged mice, the compound also reduced the production of a shock-associated toxin compared with no treatment. Next steps could include investigating the effects of the polyglycerol sulfates in other <i>in vivo</i> models of inflammatory disease.	Patent and licensing status unavailable	Dernedde, J. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online Nov. 1, 2010; doi:10.1073/pnas.1003103107 <b>Contact:</b> Rainer Haag, Institute for Chemistry and Biochemistry, Free University of Berlin, Berlin, Germany e-mail: <a href="mailto:haag@chemie.fu-berlin.de">haag@chemie.fu-berlin.de</a>
<p><b>SciBX 3(46); doi:10.1038/scibx.2010.1388</b>  <b>Published online Dec. 2, 2010</b></p>				